You may also like...

2 Responses

  1. Mike says:

    Great site that ms for sharing. Are you still using Amylin? I’m also curious if you’ve ever experimented with GLP1 agonists. Easy to get and offers similar satiating results—maybe too much in my experience. I’ve using R over the faster insulins better matches the curves though.

    • Brian says:

      Hi Mike – Thank you for writing and for your excellent questions and comments. I have been meaning to write a follow-up post about Symlin, but in a nutshell, it behaves a little differently than it did when I first started and published this post. I had to titrate up the dose a bit, and it works best if I cycle it (in other words use less for a few days, then go back to using more). I’ve capped my usage at 60mcg per meal. The satiation effect lasts for about 2-3 hours, and I’ll have zero interest in food during that time. The problem with that is if I take it before a 6PM dinner, I won’t eat enough, and then find the hunger returning around 9pm… not a good time to be hungry! So, it isn’t perfect, but I like it enough to continue using. Thank you for mentioning GLP-1 agonists. I’ve been intrigued by this for a long time – I even had a sample of Trulicity in my possession at one point. I didn’t use it because it is a once-weekly injection – meaning that it persists in your body for a long time. My fear was that with exercise, I would have serious lows. One of the mechanisms of action of GLP-1 is to inhibit inappropriate post-meal glucagon release – but you really need glucagon when you’re exercising. Is is challenging to get GLP1 as a Type 1? Supposedly it is off-label for T1d, though I have read a lot of reports of T1’s benefitting from it. Apparently >65% of long term type 1s have some residual beta cell function ( https://diabetes.diabetesjournals.org/content/59/11/2846 ). Note that in the conclusion of this paper, they suggest that “stimuli to enhance endogenous β cells could be a viable therapeutic approach in a significant number of patients with type 1 diabetes, even for those with chronic duration”. GLP-1’s main mechanism of action is to stimulate glucose-dependent insulin release from the pancreatic islets… so it is definitely promising! The question is: how to get your insurance to cover it if you’re “only” a T1?

Leave a Reply

Your email address will not be published. Required fields are marked *